Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 88 publications
Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.
Journal: Journal of atherosclerosis and thrombosis
Published: July 01, 2026
Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.
Journal: European journal of preventive cardiology
Published: December 18, 2025
Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.
Journal: Atherosclerosis
Published: December 18, 2025
Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.
Journal: Atherosclerosis
Published: October 16, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.
Journal: Journal of the American Heart Association
Published: August 23, 2025
Post-heparin plasma lipase activities in patients with severe hypertriglyceridemia treated with evinacumab.
Journal: Journal of lipid research
Published: August 12, 2025
Correction to: Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Journal: Circulation
Published: July 07, 2025
Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary.
Journal: Future cardiology
Published: June 23, 2025
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial.
Journal: Journal of clinical lipidology
Published: May 02, 2025
Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary.
Journal: Future cardiology
Published: February 11, 2025
Comparison of Model-Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 31, 2025
Population Pharmacokinetics and Exposure-Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 31, 2025
Last Updated: 09/26/2026